Antitrust Law Daily FTC establishes objectively baseless patent litigation to support AndroGel monopoly claim
News

FTC establishes objectively baseless patent litigation to support AndroGel monopoly claim

For purposes of an FTC monopolization claim based on sham litigation aimed at delaying generic competition for the testosterone replacement therapy AndroGel, patent lawsuits brought by AbbVie Inc. and...

To continue accessing free resources, please provide your email address.

This field is required
This field is required
This field is required Please Type Valid Email Address This field is required This field is required

Thank you!

We apologize!